2142 — HBM Holdings Share News
0.000.00%
Last trade - 00:00- HK$9.03bn
- HK$6.91bn
- $157.98m
HK-listed HBM rises most in near 5 weeks on Bristol Myers Squibb deal
Brief: Hbm Holdings Enters Global Strategic Collaboration And License Agreement With Bristol Myers Squibb
Hbm climbs on progress of AstraZeneca collaboration
Brief: HBM Holdings Reports Advancement Of Global Collaboration With Astrazeneca
HK-listed Hbm climbs to six-week high on licence deal with Pfizer
Brief: HBM Holdings' Unit Enters License Agreement With Pfizer
Brief: HBM Holdings Enters Agreement With Umoja Biopharma
Brief: HBM Holdings Announces Placement Of 45 Million Shares At HK$11.50 Per Share
Brief: HBM Holdings Posts HY Profit USD73 Million
Brief: HBM Holdings Expects HY Profit Between $68 MLN & $74 MLN
Brief: Harbour BioMed's Monoclonal Antibody, Enters Global Phase 2 Trial For Asthma
Brief: HBM Holdings Says Strategic Collaboration With Otsuka For HBM7020
Brief: HBM Holdings Says Co Repurchased HK$9 MLN Worth Of Shares On 17 June
Brief: HBM Holdings Says China National Intellectual Property Administration Issued Final Decision
Brief: HBM's Unit Enters Into License Agreement With Visterra
Brief: HBM Holdings Intends To Repurchase Shares Of Co
Brief: HBM Holdings To Issue To Astrazeneca Holdings Subscription Shares
Brief: Harbour Biomed Enters Into Global Strategic Collaboration With Astrazeneca
HK-listed Hbm at 3-year peak on getting paid for license deal